Litcius/Paper detail

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab

Connie H. Miller, Brian Boylan, Amanda B. Payne, Jennifer Driggers, Christopher J. Bean

2020International Journal of Laboratory Hematology20 citationsDOIOpen Access PDF

Abstract

International Journal of Laboratory HematologyVolume 43, Issue 2 p. e84-e86 LETTER TO THE EDITOR Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab Connie H. Miller, Corresponding Author Connie H. Miller [email protected] orcid.org/0000-0002-3989-7973 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USA Correspondence Connie H. Miller, Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 1600 Clifton Road MS D02, Atlanta, GA 30329, USA. Email: [email protected] for more papers by this authorBrian Boylan, Brian Boylan orcid.org/0000-0003-3930-4565 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorAmanda B. Payne, Amanda B. Payne orcid.org/0000-0003-1027-7639 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorJennifer Driggers, Jennifer Driggers Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorChristopher J. Bean, Christopher J. Bean orcid.org/0000-0001-7433-9769 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this author Connie H. Miller, Corresponding Author Connie H. Miller [email protected] orcid.org/0000-0002-3989-7973 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USA Correspondence Connie H. Miller, Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 1600 Clifton Road MS D02, Atlanta, GA 30329, USA. Email: [email protected] for more papers by this authorBrian Boylan, Brian Boylan orcid.org/0000-0003-3930-4565 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorAmanda B. Payne, Amanda B. Payne orcid.org/0000-0003-1027-7639 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorJennifer Driggers, Jennifer Driggers Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this authorChristopher J. Bean, Christopher J. Bean orcid.org/0000-0001-7433-9769 Division of Blood Disorders, Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, USASearch for more papers by this author First published: 10 November 2020 https://doi.org/10.1111/ijlh.13384Citations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume43, Issue2April 2021Pages e84-e86 RelatedInformation

Topics & Concepts

ChromogenicMedicineChemistryChromatographyHemophilia Treatment and ResearchPlatelet Disorders and TreatmentsBlood Coagulation and Thrombosis Mechanisms
Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab | Litcius